Introduction
Prostate cancer is the most common cancer in men and is also a leading cause of death in males with cancer. Prostate-specific antigen (PSA) screening plays a pivotal role in the early detection of prostate cancer. However, this prostate cancer screening test remains debatable due to the complexity of balancing the pros and cons. While the PSA screening test has undoubtedly saved lives by detecting cancer early, it has also been criticized due to the potential for overdiagnosis and overtreatment. This article will explain the pros and cons of PSA screening and underscores the delicate balance between its pros and cons.
What Is PSA Screening?
PSA, or prostate-specific antigen, is a protein produced usually by the prostate. Generally, it is found in the semen, with minimal amounts released into the bloodstream. If there is a malignancy or other issues, PSA will be produced in high amounts. A blood test can easily detect a rising PSA level. PSA screening can help detect malignancy early, so early treatment may be provided for effectiveness and potentially have fewer side effects. The PSA test was originally approved by the Food and Drug Administration (FDA) in 1986 to check prostate cancer progression in men diagnosed with prostate cancer. In 1994, the FDA approved this test to be used along with a digital rectal exam to provide a better diagnosis of prostate cancer in men.
For this test, a blood sample is drawn from the arm and sent to a laboratory for checking. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood. A higher PSA indicates a greater chance of prostate cancer, but it does not necessarily mean an individual has prostate cancer. In addition to prostate cancer, several benign conditions, such as benign prostatic hyperplasia (enlargement of the prostate) and prostatitis (prostate inflammation), can cause PSA levels to rise. In rare cases, even a lower level of PSA can result in malignancy.
What Are the Benefits of PSA Testing?
-
PSA screening has been pivotal in diagnosing prostate cancer at an initial and potentially curable stage. Early detection of cancer can increase successful treatment chances and improve survival rates.
-
PSA testing is a straightforward and convenient test. It can be done by collecting blood samples from the patient.
-
The number of deaths due to prostate cancer has dramatically reduced since the availability of PSA testing.
-
The use of PSA screening is not only for initial diagnosis but also for checking the progression of the disease in men with prostate cancer. This test can also help healthcare professionals to assess the treatment effectiveness and identify potential recurrences.
-
PSA screening helps patients to make informed decisions about their health. It allows patients and their clinicians to discuss the benefits and risks of various screening and treatment options.
What Are the Ill Effects of PSA Testing?
-
The common concern regarding PSA screening is the potential for overdiagnosis. The individuals are diagnosed with prostate cancer that may be harmless and slow growing, which never causes any symptoms during their lifetime. Overdiagnosis can pave the way to unnecessary treatments and side effects.
-
Overdiagnosis can eventually lead to overtreatment, like surgery, radiation therapy, chemotherapy, or other interventions. These treatments can be associated with various other serious side effects, such as erectile dysfunction, bowel dysfunction, urinary incontinence, and infertility, which can impact a patient's quality of life.
-
A prostate cancer diagnosis can provoke confusion, depression, and anxiety. This can affect the patient's quality of life.
-
PSA tests can produce false-positive results, leading to unwanted stress, treatments, and follow-up procedures. In the same way, they can also produce false-negative results, providing a feeling of security to individuals who may be affected by prostate cancer.
-
PSA testing has reduced the deaths caused by prostate cancer. However, the number may not be enough to justify the possibility of harm and expenses to the person undergoing the testing.
-
Other benign conditions can also elevate the PSA levels, such as prostatitis, benign prostatic hyperplasia, or infection. The lack of specificity in this test can lead to unnecessary concerns and medical procedures.
How to Balance the Pros and Cons of PSA Screening?
There are controversies regarding the benefits and harm of PSA screening. To strike a balance between the positive and negative aspects of PSA screening, several strategies have been proposed and implemented:
Informed Decision-Making - Healthcare professionals should have a decision session with the patient and share the positive and negative side of PSA screening. This will help the patients know and select what is best for them.
Healthcare professionals should provide information about the following:
-
Benefits of early prostate cancer detection.
-
Risks of overdiagnosis and overtreatment.
-
Side effects of treatments for prostate cancer.
-
Limitations of the PSA screening test in accurately diagnosing cancer.
-
Uncertainties about prostate cancer, including the chance of cancer progression.
Risk Stratification - Risk stratification means categorizing patients into risk groups based on the probability of developing prostate cancer. By planning specialized screening recommendations for these risk groups, the risk of overdiagnosis and overtreatment can be reduced while still providing early detection to the required individuals.
Active Surveillance - Active surveillance is a strategy used to reduce the negative effects of overdiagnosis and overtreatment in prostate cancer. This method is advocated for men diagnosed with low-risk prostate cancer, whose chance of causing harm or progression is minimal during their lifetime.
Advancements in Testing - Recent technologies have improved the specificity and accuracy of PSA tests. So, the test is more reliable in distinguishing between low-grade and high-grade forms of prostate cancer.
Multifaceted Approach - It is important to note that only a single approach may not provide results to the PSA screening dilemma. So, a multifaceted approach is required, combining informed decision-making, risk assessment, and advancing medical technology to achieve a balanced approach.
Conclusion
The controversy regarding PSA screening is a complicated and evolving issue in prostate cancer diagnosis and treatment. The delicate balance between the benefits and harm of PSA screening can be obtained by following certain strategies. The strategies include informed decision-making, risk stratification, active surveillance, advancements in testing, and a multifaceted approach, which will help to minimize the PSA screening risks.
